AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction
Open Access
- 14 April 2026
- journal article
- review article
- Published by Wiley in Addiction Biology
- Vol. 31 (4) , e70152
Abstract
Although the angiotensin II type 1 receptor (AT1R), a pivotal component of the renin–angiotensin system (RAS), is associated with cardiovascular and renal homeostasis, burgeoning evidence implicates its critical role in neuropsychiatric disorders, particularly addiction. Beyond regulating haemodynamics, AT1R activation in the central nervous system (CNS) modulates neuroinflammatory cascades, dopaminergic signalling plasticity, and stress‐responsive neural circuit processes central to addiction pathophysiology. Notably, preclinical studies reveal that AT1R blockade attenuates drug‐seeking behaviours by normalizing mesolimbic dopamine dysregulation and reducing glutamatergic excitotoxicity in the nucleus accumbens. This review systematically integrates contemporary evidence elucidating the dual pathophysiological roles of AT1R in CNS disorders, with particular emphasis on neurodegenerative diseases and psychiatric conditions. Crucially, we delineate two mechanistically distinct yet interconnected functions of AT1R: (1) serving as a critical mediator of maladaptive neuroplasticity during protracted exposure to addictive substances and (2) functioning as a regulator of blood–brain barrier (BBB) integrity, thereby potentiating neurotoxicant infiltration in substance use disorders. Building upon these mechanistic insights, we propose a translational framework for repurposing clinically approved AT1R antagonists as novel pharmacotherapies targeting addiction‐related neurocircuitry dysregulation. By bridging molecular insights with translational opportunities, this work positions AT1R as a novel therapeutic target to address unmet clinical needs in addiction.Keywords
Funding Information
- National Natural Science Foundation of China (82301680)
This publication has 150 references indexed in Scilit:
- Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan SyndromeScience, 2006
- The Neural Basis of Addiction: A Pathology of Motivation and ChoiceAmerican Journal of Psychiatry, 2005
- Dual Angiotensin II and Endothelin A Receptor Antagonists: Synthesis of 2‘-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and PharmacokineticsJournal of Medicinal Chemistry, 2004
- The brain renin–angiotensin system: location and physiological rolesThe International Journal of Biochemistry & Cell Biology, 2003
- ΔFosB: A sustained molecular switch for addictionProceedings of the National Academy of Sciences, 2001
- Molecular basis of long-term plasticity underlying addictionNature Reviews Neuroscience, 2001
- International Union of Pharmacology. XXIII. The Angiotensin II ReceptorsPharmacological Reviews, 2000
- Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream MedicineAnnals of the New York Academy of Sciences, 2000
- Expression of Angiotensin Type-1 (AT1) and Type-2 (AT2) Receptor mRNAs in the Adult Rat Brain: A Functional Neuroanatomical ReviewFrontiers in Neuroendocrinology, 1997
- Astrocytes Synthesize Angiotensinogen in BrainScience, 1988